Literature DB >> 23910647

Hospitalizations due to hepatitis C in Los Angeles County, 2007-2009: case characteristics and factors associated with mortality.

L Sie1, N M Gatto, E Bancroft.   

Abstract

Morbidity and mortality due to hepatitis C (HCV) infection are rising in the United States as the highest risk cohort (those born between 1945 and 1965) ages. It is important for governments and healthcare providers to have timely, readily obtainable data to estimate the burden of HCV locally. Demographic factors, hospital charges and comorbid conditions were summarized for Los Angeles County (LAC) residents who had at least one hospitalization in California during 2007-2009 with HCV as a primary or secondary diagnosis using statewide hospital discharge data. Logistic regression was used to estimate odds ratios for factors associated with dying during hospitalization. A total of 19 907 unique patients were hospitalized with HCV during the 3-year study period; 63.0% were aged 45-65 years; 1874 (9.4%) died. Hospitalizations for HCV doubled during this time period. Total charges for hospitalizations for which HCV was coded as the principal diagnosis increased from $18 million to $58 million, with over 70% charged to government sources. After adjusting for demographic factors, human immunodeficiency virus (HIV) and hepatitis B (HBV), current alcohol abuse and kidney disease were associated with dying during hospitalization. Based on statewide hospital discharge data, morbidity and mortality from HCV infections increased in LAC from 2007-2009, and pose an economic burden to government. To lower mortality risk, HCV patients should be referred for follow-up. The expected increase in HCV hospitalizations as infected patients' age poses an increasing burden to healthcare systems.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Los Angeles; OSHPD; hepatitis C; hospitalizations; mortality; surveillance

Mesh:

Year:  2013        PMID: 23910647     DOI: 10.1111/jvh.12086

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Authors:  Rae Jean Proeschold-Bell; Donna M Evon; Christina Makarushka; John B Wong; Santanu K Datta; Jia Yao; Ashwin A Patkar; Paolo Mannelli; Terra Hodge; Susanna Naggie; Julius M Wilder; Michael W Fried; Donna Niedzwiecki; Andrew J Muir
Journal:  Contemp Clin Trials       Date:  2018-07-10       Impact factor: 2.226

2.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

3.  Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.

Authors:  Haesuk Park; Donghak Jeong; Pauline Nguyen; Linda Henry; Joseph Hoang; Yoona Kim; Edward Sheen; Mindie H Nguyen
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

4.  National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996-2010 in the United States: a cross-sectional study.

Authors:  Christine U Oramasionwu; Joshua C Toliver; Terence L Johnson; Heather N Moore; Christopher R Frei
Journal:  BMC Infect Dis       Date:  2014-10-10       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.